Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today that it has been named the 8 th Fastest Growing Company in New Jersey according to NJBiz at the 2011 50 Fastest Growing Companies of NJ award ceremony held in Somerset, NJ last night.

Marc D. Grodman, MD, CEO, commented: “We welcome the recognition of NJBiz and the sponsoring organizations. We congratulate all the companies that were recognized by NJBiz, and we especially congratulate the loyal and valued employees of BioReference Laboratories who have made BioReference such a special company.”

About BioReference Laboratories, Inc.

BRLI is the fourth largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing laboratory servicing physician offices with concentrations in the focused markets of esoteric testing, molecular diagnostics, anatomical pathology, women’s health and correctional health care. BRLI operates as a national oncology laboratory as GenPath. Better science, superior technology and better service have enabled GenPath to earn a reputation as one of the premier hematopathology laboratories in the country. BRLI’s innovative technology platform for sexually transmitted infections has enabled it to expand as a national laboratory in the area of Women’s Health. GeneDx, a wholly owned subsidiary, is the BRLI genetics laboratory and is typically recognized as the leading laboratory for testing of rare genetic diseases; GeneDx has now become a technology leader with GenomeDx, based on a CGH array platform and its NextGen sequence offerings that are currently offered in cardiology and will be offered in the future in other disease specific areas.

Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as “forward-looking statements”. Statements looking forward in time are included in this release pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to be materially different from any future performance suggested herein.

Copyright Business Wire 2010